참고문헌
- Ahmadi AS, Mahdipour L, Payandeh M, et al (2015). Epidemiology, pathology and histochemistry features in women with breast cancer. Am J Cancer Prev, 3, 54-7.
- Camerini A, Donati S, Viacava P, et al (2011). Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res, 30, 38. https://doi.org/10.1186/1756-9966-30-38
- Carey LA, Perou CM, Livasy CA, et al (2006). Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA, 295, 2492-502. https://doi.org/10.1001/jama.295.21.2492
- el AT, Khalifa A, Kamel AS (2000). Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt. Anticancer Res, 20, 2145-50.
- Fountzilas G, Valavanis C, Kotoula V, et al (2012). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med, 10, 10. https://doi.org/10.1186/1479-5876-10-10
- Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8. https://doi.org/10.7314/APJCP.2013.14.7.4353
- Hayashi N, Niikura N, Masuda N, et al (2015). Prognostic factors of HER2-positive breast cancer patients who develop brain metastasis: a multicenter retrospective analysis. Breast Cancer Res Treat, 149, 277-84. https://doi.org/10.1007/s10549-014-3237-7
- Inwald EC, Klinkhammer-Schalke M, Hofstadter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat, 139, 539-52. https://doi.org/10.1007/s10549-013-2560-8
- Kai K, Nishimura R, Arima N, et al (2006). p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study. Int J Clin Oncol, 11, 426-33. https://doi.org/10.1007/s10147-006-0601-6
- Lee DS, Kim SH, Suh YJ, et al (2011). Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol, 41, 854-66. https://doi.org/10.1093/jjco/hyr066
- Li FY, Wu SG, Zhou J, et al (2014). Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One, 9, 87264. https://doi.org/10.1371/journal.pone.0087264
- Menard S, Fortis S, Castiglioni F, et al (2001). HER2 as a prognostic factor in breast cancer. Oncol, 61, 67-72. https://doi.org/10.1159/000055404
- Nishimura R, Osako T, Okumura Y, et al (2010). Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med, 1, 747-54. https://doi.org/10.3892/etm.2010.133
- Patnayak R, Jena A, Rukmangadha N, et al (2015). Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol, 36, 117-22. https://doi.org/10.4103/0971-5851.158844
- Payandeh M, Khodarahmi R, Sadeghi M, et al (2015a). Appearance of acute myelogenous leukemia (AML) in a patient with breast cancer after adjuvant chemotherapy: case report and review of the literature. Iran J Cancer Prev, 8, 125-8.
- Payandeh M, Sadeghi M, Sadeghi E, et al (2015b). Clinicopathology figures and long-term effects of tamoxifen plus radiation on survival of women with invasive ductal carcinoma and triple negative breast cancer. Asian Pac J Cancer Prev, 16, 4863-7. https://doi.org/10.7314/APJCP.2015.16.12.4863
- Shokouh TZ, Ezatollah A, Barand P (2015). Interrelationships Between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study. Med (Baltimore), 94, 1359. https://doi.org/10.1097/MD.0000000000001359
- Swede H, Moysich KB, Freudenheim JL, et al (2001). Breast cancer risk factors and HER2 over-expression in tumors. Cancer Detect Prev, 25, 511-9.
- Wiesner FG, Magener A, Fasching PA, (2009). Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients. Breast, 18, 135-41. https://doi.org/10.1016/j.breast.2009.02.009
- Yamamoto M, Hosoda M, Nakano K, et al (2014). p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci, 105, 81-8. https://doi.org/10.1111/cas.12302
- Yarden Y (2001). Biology of HER2 and its importance in breast cancer. Oncol, 61, 1-13.
피인용 문헌
- Machine learning approaches to decipher hormone and HER2 receptor status phenotypes in breast cancer pp.1477-4054, 2017, https://doi.org/10.1093/bib/bbx138
- Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer vol.16, pp.1, 2018, https://doi.org/10.1186/s12967-018-1495-6
- HER2 overexpression and correlation with other significant clinicopathologic parameters in Ivorian breast cancer women vol.19, pp.1, 2019, https://doi.org/10.1186/s12907-018-0081-4
- Correlation Between HER-2 Gene Amplification or Protein Expression and Clinical Pathological Features of Breast Cancer vol.34, pp.1, 2019, https://doi.org/10.1089/cbr.2018.2576